A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy

• Päätekijät: Cristina Ioana Barbălată (Tekijä), Alina Silvia Porfire (Tekijä), Alina Sesarman (Tekijä), Valentin-Florian Rauca (Tekijä), Manuela Banciu (Tekijä), Dana Muntean (Tekijä), Rareș Știufiuc (Tekijä), Alin Moldovan (Tekijä), Cristian Moldovan (Tekijä), Ioan Tomuță (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2021-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing...